Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 17/20 | 0.48 |
| ▸ | TYK2 | P29597 | 16/20 | 0.48 |
| ▸ | JAK1 | P23458 | 16/20 | 0.48 |
| ▸ | JAK2 | O60674 | 15/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22054133 | 1.00 | JAK3 (0.48) | JAK3TYK2JAK1JAK2KAT2B | |
| SCHEMBL23889388 | 0.85 | TYK2 (0.41) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL23889390 | 0.81 | SUV39H2 (0.47) | KAT2BGPR119 | |
| SCHEMBL22054131 | 0.81 | SUV39H2 (0.47) | KAT2BGPR119 | |
| SCHEMBL30923649 | 0.81 | JAK3 (0.48) | JAK3TYK2JAK1JAK2KAT2B | |
| SCHEMBL23878845 | 0.80 | TYK2 (0.58) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL22054114 | 0.80 | TYK2 (0.58) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL31304735 | 0.80 | TYK2 (0.58) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL18269689 | 0.79 | TYK2 (0.75) | JAK3TYK2JAK1JAK2 | |
| SCHEMBL29512168 | 0.79 | TYK2 (0.75) | JAK3TYK2JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003441-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-115925705-B | Heteroaromatic derivative regulator, preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | JAK3 88/4885TYK2 105/4885JAK1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.